Exegenesis Bio To Present Five Posters at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, Los Angeles, CA, May 16-20, 2023

Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce the presentation of five posters at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles, California, May 16 to 20, 2023.

Exegenesis Bio will present nonhuman primate data from its novel muscle-directed capsid development program, comparing the muscle transduction of its proprietary AAV capsid variants with the most potent muscle-directed capsids known to date. The company will also present further safety and efficacy data from its novel, clinical stage wet Age-Related Macular Degeneration (wAMD) gene therapy program, EXG102-031.

Exegenesis Bio will present the following five posters at the 2023 ASGCT meeting:

1. AAV9 Variants Engineered for More Efficient Muscle Transduction Using AAVarta^TM (a Proprietary AI-Aided AAV Capsid Evolution Discovery Technology) Demonstrate Improved Muscle Transduction Versus AAV9 and MyoAAV4A
2. Ongoing Safety and Efficacy of EXG102-031, a Novel Clinical Stage AAV-based Gene Therapy for Neovascular AMD Expressing a Therapeutic Fusion Protein that Binds/Neutralizes All Known Subtypes of VEGF and ANG2
3. Intravenous Administration of a Very Low Dose AAV-GLA Gene Therapy Corrects Substrate Levels and Demonstrates Strong Efficacy in the Mouse Model of Fabry Disease
4. Safe and Efficient Intra-CSF Delivery of AAV Vector in Nonhuman Primates Leads to Improved Transgene Expression in the Central Nervous System and Demonstrates a Robust Safety Profile
5. A Next-Generation AAV Gene Therapy for Spinal Muscular Atrophy Can Avoid Systemic High-Dose AAV Administration and Improve Safety and Efficacy

“I congratulate our team for advancing our proprietary AI-aided capsid discovery programs into nonhuman primates and generating industry-leading data, while also moving our clinical programs into IND-enabling and early-stage clinical studies. This is strong validation of the world-class capsid discovery platform that our company has built and the novel gene therapy constructs that our team has designed. We are now at an exciting stage of our journey where we are ready to partner with other companies to advance our highly promising muscle capsids into clinical development and bring our innovative gene therapies to patients worldwide,” stated Zhenhua Wu, CEO of Exegenesis Bio.